The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Open accessAbstract
BACKGROUND: The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity. METHODS: We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome. Patients were negative for the FIP1L1-PDGFRA fusion gene and required prednisone monotherapy, 20 to 60 mg per day, to maintain a stable clinical status and a blood eosinophil count of less than 1000 per microliter. Patients received either intravenous mepolizumab or placebo while the prednisone dose was tapered. The primary end point was the reduction of the prednisone dose to 10 mg or less per day for 8 or more consecutive weeks. RESULTS: The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P<0.001) with no increase in clinical activity of the hypereosinophilic syndrome. A blood eosinophil count of less than 600 per microliter for 8 or more consecutive weeks was achieved in 95% of patients receiving mepolizumab, as compared with 45% of patients receiving placebo (hazard ratio, 3.53; 95% CI, 1.94 to 6.45; P<0.001). Serious adverse events occurred in seven patients receiving mepolizumab (14 events, including one death; mean [+/-SD] duration of exposure, 6.7+/-1.9 months) and in five patients receiving placebo (7 events; mean duration of exposure, 4.3+/-2.6 months). CONCLUSIONS: Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic syndrome. (ClinicalTrials.gov number, NCT00086658 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Rothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
Self-citationThe hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.
Chusid, M. J., Dale, D. C., West, B. C., & Wolff, S. M. (1975) · PubMed · Cited by 1,233
THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature
CHUSID, M. J., DALE, D. C., WEST, B. C., & WOLFF, S. M. (1975) · Medicine · doi:10.1097/00005792-197501000-00001 · Cited by 1,078
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 976
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.bloodjournal79123101 · Cited by 972
Recombinant human interleukin 5 is a selective activator of human eosinophil function.
Lopez, A. F., Sanderson, C. J., Gamble, J. R., Campbell, H. D., Young, I. G., & Vadas, M. A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.1.219 · Cited by 951
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730
Cited by
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,680
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,094
Self-citationType 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Valent, P., Klion, A. D., Horny, H.-P., Roufosse, F., Gotlib, J., Weller, P. F., Hellmann, A., Metzgeroth, G., Leiferman, K. M., Arock, M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.019 · Cited by 767
Self-citationTH2 cell development and function
Walker, J. A., & McKenzie, A. N. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.118 · Cited by 632
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Ogbogu, P. U., Bochner, B. S., Butterfield, J. H., Gleich, G. J., Huss-Marp, J., Kahn, J. E., Leiferman, K. M., Nutman, T. B., Pfab, F., Ring, J., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.022 · Cited by 629
Self-citationStraumann, A., Conus, S., Grzonka, P., Kita, H., Kephart, G., Bussmann, C., Beglinger, C., Smith, D. A., Patel, J., Byrne, M., et al. (2010) · Gut · doi:10.1136/gut.2009.178558 · Cited by 598
Self-citationSpergel, J. M., Rothenberg, M. E., Collins, M. H., Furuta, G. T., Markowitz, J. E., Fuchs, G., O’Gorman, M. A., Abonia, J. P., Young, J., Henkel, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.044 · Cited by 556
Self-citationEosinophil Granule Proteins: Form and Function
Acharya, K. R., & Ackerman, S. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.546218 · Cited by 526
Targeting eosinophils in allergy, inflammation and beyond
Fulkerson, P. C., & Rothenberg, M. E. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3838 · Cited by 482
Self-citationAssa'ad, A. H., Gupta, S. K., Collins, M. H., Thomson, M., Heath, A. T., Smith, D. A., Perschy, T. L., Jurgensen, C. H., Ortega, H. G., & Aceves, S. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.044 · Cited by 435
IL-5- and eosinophil-mediated inflammation: from discovery to therapy
Kouro, T., & Takatsu, K. (2009) · International Immunology · doi:10.1093/intimm/dxp102 · Cited by 422
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
Fajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
Chapter 3 Biology of the Eosinophil
Blanchard, C., & Rothenberg, M. E. (2009) · Advances in Immunology · doi:10.1016/s0065-2776(08)01003-1 · Cited by 345
Self-citationRefining the definition of hypereosinophilic syndrome
Simon, H.-U., Rothenberg, M. E., Bochner, B. S., Weller, P. F., Wardlaw, A. J., Wechsler, M. E., Rosenwasser, L. J., Roufosse, F., Gleich, G. J., & Klion, A. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.042 · Cited by 338
Self-citationTakatsu, K., & Nakajima, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.001 · Cited by 320
Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Takaki, S., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101270 · Cited by 314
Hercus, T. R., Thomas, D., Guthridge, M. A., Ekert, P. G., King-Scott, J., Parker, M. W., & Lopez, A. F. (2009) · Blood · doi:10.1182/blood-2008-12-164004 · Cited by 307
Interleukin-5 and IL-5 receptor in health and diseases
TAKATSU, K. (2011) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.87.463 · Cited by 297
Therapies for allergic inflammation: refining strategies to induce tolerance
Akdis, C. A. (2012) · Nature Medicine · doi:10.1038/nm.2754 · Cited by 296
How I treat hypereosinophilic syndromes
Klion, A. D. (2015) · Blood · doi:10.1182/blood-2014-11-551614 · Cited by 296
Self-citationInflammatory Cardiomyopathic Syndromes
Trachtenberg, B. H., & Hare, J. M. (2017) · Circulation Research · doi:10.1161/circresaha.117.310221 · Cited by 289
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280
Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Emerging Roles for Eosinophils in the Tumor Microenvironment
Reichman, H., Karo-Atar, D., & Munitz, A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.002 · Cited by 116
Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis
Kuchynka, P., Palecek, T., Masek, M., Cerny, V., Lambert, L., Vitkova, I., & Linhart, A. (2016) · BioMed Research International · doi:10.1155/2016/2829583 · Cited by 96
Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome
Kuang, F. L., Fay, M. P., Ware, J., Wetzler, L., Holland-Thomas, N., Brown, T., Ortega, H., Steinfeld, J., Khoury, P., & Klion, A. D. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.033 · Cited by 94
Self-citationCheung, C. C., Constantine, M., Ahmadi, A., Shiau, C., & Chen, L. Y. C. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.04.002 · Cited by 78
Metadata
- Authors
- Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J. E., Weller, P. F., Simon, H.-U., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., Haig, A. E., Frewer, P. I. H., Parkin, J. M., & Gleich, G. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-20
- Volume
- 358
- Issue
- 12
- Pages
- 1215-1228
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155730304
- Cited by
- 583
- References
- 29
- FWCI
- 33.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.